This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
NEW YORK, July 3, 2013 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq:STML) announced today that Ivan Bergstein, M.D., Chief Executive Officer, will present at the 8
th Annual JMP Securities Healthcare Conference on Wednesday, July 10, 2013 at 11:00 a.m. ET. The conference will take place at the St. Regis Hotel in New York, NY. A live webcast and 30-day archive of the event can be viewed at the Company's website at
About Stemline Therapeutics, Inc.
Stemline Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing novel oncology therapeutics that target both cancer stem cells (CSCs) as well as the tumor bulk. Stemline's clinical candidates, SL-401 and SL-701, have demonstrated clinical activity, including durable complete responses (CRs), in Phase 1/2 studies of patients with advanced hematological and brain cancer, respectively. For more information about Stemline Therapeutics, visit
www.stemline.com . The information in our website is not incorporated by reference into this press release and is included as an inactive textual reference only.
Some of the statements included in this press release may be forward-looking statements that involve a number of risks and uncertainties. For those statements, we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. The factors that could cause our actual results to differ materially are identified from time to time in our reports filed with the Securities and Exchange Commission. Any forward-looking statements set forth in this press release speak only as of the date of this press release. We do not intend to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof.
CONTACT: Stemline Contact:
Director, Corporate Development
Stemline Therapeutics, Inc.
750 Lexington Avenue
New York, NY 10022